Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

TERMINATED

Identifier: CI-TRIAL-00054861
Entity page: /trial/NCT01620216 ↗
Edges: 16

Neighbours: 4 cancers8 drugs
Drawn: 12 of 12 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia condition of …CONDITION_OFderived6 of 6
← condition of	Acute Lymphoblastic Leukemia registry condition “Recurrent Acute Lymphoblastic Leukemia” mapped CURATED_BROADER	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
← condition of	Acute Lymphoblastic Leukemia registry condition “Refractory Acute Lymphoblastic Leukemia” mapped CURATED_BROADER

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia intervention of …INTERVENTION_OFderived10 of 10
← intervention of	Dasatinibsmall molecule registry intervention “Dasatinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Idelalisibsmall molecule registry intervention “Idelalisib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pacritinibsmall molecule registry intervention “Pacritinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ponatinibsmall molecule registry intervention “Ponatinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ponatinibsmall molecule registry intervention “Ponatinib Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Ruxolitinibsmall molecule registry intervention “Ruxolitinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Sorafenibsmall molecule registry intervention “Sorafenib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Sorafenib Tosylatesmall molecule registry intervention “Sorafenib Tosylate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Sunitinibsmall molecule registry intervention “Sunitinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Sunitinibsmall molecule registry intervention “Sunitinib Malate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia intervention of …INTERVENTION_OFderived10 of 10

← intervention of

Dasatinibsmall molecule

registry intervention “Dasatinib” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Idelalisibsmall molecule

registry intervention “Idelalisib” (DRUG) mapped ALIAS

—